EUVIMEDEUVIMED entdecken
Crossref

Clinicopathologic evaluation of dedifferentiated liposarcoma lacking MDM2 amplification

Charlotte I Wang iD, Soma Jobbagy iD, Anne B Giersch iD, Jonathan B Greer iD, Kevin X Liu iD, Gregory M Cote iD, Yin P Hung iD, G Petur Nielsen iD, Ivan Chebib iD

Histopathology · 2026

DOI: 10.1111/his.70174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Charlotte I Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Liposarcoma, Retroperitoneal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dedifferentiated liposarcoma (DDLPS) is a typically non‐lipogenic malignant neoplasm that arises from progression of an underlying atypical lipomatous tumour/well‐differentiated liposarcoma (ALT/WDLPS) and is classically defined by amplification of chromosome 12q15, including MDM2 and frequently cyclin‐dependent kinase 4 ( CDK4 ). Detection of MDM2 amplification by fluorescence in situ hybridization (FISH) and/or MDM2 protein expression immunohistochemistry (IHC) has, therefore, become central to the diagnosis of DDLPS, particularly in small biopsies from the retroperitoneum. Rare exceptions to this paradigm have been described, but the clinicopathologic and molecular spectrum of MDM2 non‐amplified DDLPS remains poorly characterized. We report a series of MDM2 non‐amplified DDLPS to better define their diagnostic features, genomic alterations and clinical behaviour.

Methods

Pathology archives from 2010 to 2025 were queried for cases diagnosed as DDLPS. Inclusion criteria required a high‐grade sarcoma arising in a histologically confirmed ALT/WDLPS background, absence of MDM2 overexpression by IHC and lack of MDM2 amplification by FISH and/or single nucleotide polymorphism array. Clinicopathologic features, immunophenotype, treatment and outcomes were reviewed.

Results

Among 253 cases of DDLPS identified during the study period, four (1.6%) fulfilled criteria for MDM2 ‐negative DDLPS. All tumours arose in the retroperitoneum or intra‐abdominal soft tissues and demonstrated high‐grade sarcoma morphology with an associated WDLPS component on resection. Despite the absence of MDM2 amplification, all cases showed strong CDK4 expression by IHC. Molecular analysis revealed recurrent alterations involving cell‐cycle regulation, including CDK4 copy number gain in all cases and loss of CDKN2A in three. Two cases harboured TP53 alterations. Clinically, outcomes were heterogeneous, ranging from aggressive disease with rapid recurrence and death within months to prolonged disease‐free survival exceeding 5 years.

Conclusion

MDM2 non‐amplified DDLPS represents a rare subset of DDLPS that appear to be driven by alternative mechanisms of cell‐cycle dysregulation, most commonly involving CDK4 gain and CDKN2A loss, with occasional TP53 alterations. Awareness of this variant is critical to avoid misclassification as other high‐grade sarcomas, particularly on limited biopsies, and underscores the importance of integrating morphology, IHC and broad genomic profiling in diagnostically challenging retroperitoneal sarcomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2LiposarcomaRetroperitoneal NeoplasmsHumansGene AmplificationFemaleMiddle AgedMaleAgedAdultIn Situ Hybridization, FluorescenceAged, 80 and overBiomarkers, TumorCyclin-Dependent Kinase 4Immunohistochemistry

Stichwörter der Autor:innen

CDK4CDKN2AMDM2dedifferentiatedliposarcomasarcoma

Substanzen

Proto-Oncogene Proteins c-mdm2MDM2 protein, humanBiomarkers, TumorCyclin-Dependent Kinase 4CDK4 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Charlotte I Wang, Soma Jobbagy, Anne B Giersch, Jonathan B Greer, Kevin X Liu, Gregory M Cote, Yin P Hung, G Petur Nielsen, Ivan Chebib

Zitieren

APA

Wang, C. I., Jobbagy, S., Giersch, A. B., Greer, J. B., Liu, K. X., Cote, G. M., Hung, Y. P., Nielsen, G. P., & Chebib, I. (2026). Clinicopathologic evaluation of dedifferentiated liposarcoma lacking MDM2 amplification. Histopathology. https://doi.org/10.1111/his.70174

Vancouver

Wang CI, Jobbagy S, Giersch AB, Greer JB, Liu KX, Cote GM, et al. Clinicopathologic evaluation of dedifferentiated liposarcoma lacking MDM2 amplification. Histopathology. 2026. doi:10.1111/his.70174

BibTeX
@article{Wang2026,
  author = {Wang, Charlotte I and Jobbagy, Soma and Giersch, Anne B and Greer, Jonathan B and Liu, Kevin X and Cote, Gregory M and Hung, Yin P and Nielsen, G Petur and Chebib, Ivan},
  title = {Clinicopathologic evaluation of dedifferentiated liposarcoma lacking MDM2 amplification},
  journal = {Histopathology},
  year = {2026},
  doi = {10.1111/his.70174}
}
Kostenlos starten →